

Date: 14.02.2025

To

BSE Limited P.J.Towers, Dalal Street, Mumbai - 400001 BSE - Code : 532660

National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam,

Sub: Integrated Filing (Financial) for the Quarter and Nine Months ended December 31, 2024.

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are herewith submitting the Integrated Filing (Financial) for the Quarter and Nine Months ended December 31, 2024.

Request you to take the same on record.

Yours faithfully For VIVIMED LABS LIMITED

SANTOSH VARALWAR

MANAGING DIRECTOR



Vivimed Labs Limited. CIN:L02411KA1988PLC009465 Registered Office: #78/A, Kothar Industrial Area. Bidar, Kamataka - 565 403, India. T+91(0)8482-232045.F+91(0)8482-232436 Email: info@vivimedlabs.com / www.vivimedlabs.com

Corporate Office:

6-3-866/1/G1, 3rd Floor, GMR Towers, Greenlands, Begumpet, Hyderabad, Telangana - 500 016, India. GSTIN: 36AAACV6060A 1ZQ T +91(0) 40-6608-6608. F +91(0) 40-6608-6699

Total reconst from speciations 355.70 247.72 614 462 996.55 1,765.85 1,660 2 Other hearms 6.67 6.27 0.39 1.54 23.51 33.23 33.24 33.24 33.24 33.24 33.24 33.24				ABS LIMITED					
St. Na Per toolars St. Na St		UNAUDITED CONSOLIDATED	FINANCIAL RESULTS	FOR THE QUARTER	& NINE MONTHS ENDED 31.12	2.2024			
S. No Periodes MT/25 MT/25 MT/22 Ver Ex.4d 310.300 112.2024 309.3024 3112.2024					Rs in Million				
Income from Operations (Unmultide)	Sl. Na	a. Perticulars		3 Months Euded			9M FY 24	Year En de d 31.03.2024	
Income From Operations 365.10 207.72 416.62 900.55 1,100.55 1,400.55 Tail arcsing from appendities 365.10 207.72 416.62 900.55 1,100.55 1,400.55 Tail arcsing from appendities 365.10 2.07 0.237 0.237 0.235 35.33 Tail Arcsing from appendities 365.17 2.17.24 345.51 39.35 Cost of material constanced 167.73 214.59 300.00 57.066 88.56 Cost of material constanced 167.74 214.59 300.00 57.066 88.56 Cost of material constance 167.74 124.59 300.00 57.066 88.56 Cost of material constance 147.74 124.59 300.00 57.066 88.56 Deprice transmented 129.71 37.266 309.276 309.277.26 120.47 327.66 309.277.66 Deprice transmented 129.71 37.662 326.61 120.71 37.265.82 120.99 327.66 329.766 329.766 329.776									
I Remue from operations 363.0 247.22 44.62 90.635 1,104.55 1,600.55 1 Other from one Constructions 0.67 0.27 0.29 1.54 2.25.1 39.3 2 Other from one Constructions 0.67 0.27 0.29 1.54 2.25.1 39.3 3 Total account of one operations 0.67 0.27 0.29 1.54 2.25.1 39.3 3 Total account of one operations 0.67 0.27.9 41.56 9.86.66 1.56.6			(Unaudited)	(Linaudited)	(Unaudited)	(Linaudsted)	{Unaudsted}	(Audited)	
Total resume from operations 365.70 377.72 414.62 996.55 1,166.55 1,460.70 2 Other immem 6.67 0.27 0.39 1.54 23.53 39.20 3 Total secure (1/2) 6.67 0.27 0.39 1.54 23.53 39.20 4 Expresse 6.67 0.27 0.39 1.54 23.55 1.96.64 5 Cot of material consumed 6.67 0.27 0.39 5.56 (10.75) 6 Cot of material consumed 167.74 154.77 214.59 50.002 57.064 88.54 6 Cot of material consumed 167.74 154.77 214.59 5.56 (10.75) 7.64 145.71 214.59 5.56 (10.75) 35.50 23.55 (10.75) 35.50 23.55 (10.75) 35.50 23.55 (10.75) 35.50 23.55 (10.75) 35.50 23.55 (10.75) 35.50 23.55 (10.75) 35.50 23.55 23.55 23.55 23.55 23.55 23.55 </td <td></td> <td>buome rion Operations</td> <td></td> <td></td> <td></td> <td>-</td> <td>i i</td> <td></td>		buome rion Operations				-	i i		
2 Citer income 6.67 6.27 0.39 1.54 22.53 9.92 3 Tutk Render (17) 36.77 247.99 415.01 996.69 1.22.59 1.996.69 4 Exponse 15.74 15.87 22.459 5.0002 5.70.64 885.64 Constrained normand 15.74 15.87 22.459 5.0002 5.70.64 885.64 Constrained normalised function of normalised pools work its progress and stock-in-Trade 44.33 427 132.11 120.07 55.66 3.43.3 4 Dimensional Americation Exponses 44.33 427 132.11 120.07 55.76 3.43.3 5 Dift born at 3-41 (29.72) (27.64) 867.64 127.79 1.05.82 2.99.66 7 Total Exponses 48.37 7.76.1 867.64 127.79 1.05.82 1.996.69 7 Total Exponses 69.77 0.77.79 1.66.63 (26.45.01) (27.69) (38.99 7 Total Exponses	1	Recenue from operations	365.10	247.72	414.62	906.55	1,104.55	1,490.71	
3 Tail Resource (1*2) 365.77 247.99 415.01 906.00 1.222.06 1.900.4 4 Exprose Cost of material construend 167.14 155.47 222.06 570.64 885.5 6 Cargo interial construence 167.14 155.47 222.06 570.64 885.5 6 Cargo interial construence 167.14 155.47 222.06 570.64 885.5 6 Cargo interial construence 167.14 155.47 222.06 770.64 885.5 7 Depression interactions of philoid goods use in progress and stock-in-Trade 167.14 115.27 212.80.67 234.14 6 Dispression interactions of philoid goods use in progress and stock-in-Trade 64.15 41.00 47.04 147.20 334.5 345.5 7 Depression interactions of philoid goods use in progress and stock-in-Trade 64.15 41.00 45.02 167.04 147.20 334.5 345.5 345.5 345.5 345.5 700.22 12.990.64 177.00 1.60.26 167.05 167.05 167.05 167.05 167.05 102.05 107.05 <t< td=""><td></td><td>Total revenue from operations</td><td>365.10</td><td>247.72</td><td>414.62</td><td>906.55</td><td>1,104.55</td><td>1,490.71</td></t<>		Total revenue from operations	365.10	247.72	414.62	906.55	1,104.55	1,490.71	
4 Spanse 1167.14 115.47.1 214.59 5000 570.64 865.4 C Carrys in triorotics of finished goods work in progress and stock in Trade 443.2 115.47.1 115.47.1 214.59 5000.0 570.64 865.4 C Employee Briefit Asymmets 443.2 112.17.1 1000.0 570.64 343.4 P Procession and Ammitistion Expenses 443.2 132.11 1200.7 337.66 343.4 P Procession and Ammitistion Expenses 443.2 132.11 1200.7 337.66 343.4 C Paymets 443.2 132.11 1200.7 337.66 343.4 P Procession and Ammitistion Expenses 443.2 123.70 1.663.40 (23.47.70 1.663.40 (23.47.70 1.653.40 1.17.70 1.653.40 1.17.70 1.653.40 (23.57.70 6.54.40 (23.57.70 6.54.40 (23.57.70 6.54.40 (23.57.70 6.54.40 (23.57.70 6.54.40 (23.57.70 6.54.40 (23.57.70.70 6.54.40 <	2	Other Income	0.67	0.27	0.39	1.54	23.51	99.76	
a Cost of material construined 147.74 115.71 214.59 500.02 570.64 885.5 b Charge bench Express 145.74 115.71 214.59 500.02 570.64 885.5 c Employee bench Express 145.74 115.93 3.05 1.55.45 52.26 (18.07 c Employee bench Express 64.85 97.54 196.07 271.64 343.5 c Depreciation and Ammitation Express 66.15 41.00 47.74 147.23 141.06 139.9 c Depreciation and Ammitation Express 66.15 295.60 351.64 21.71.70 1.652.82 2.980.64 c Depreciation and Ammitation Express 65.15 (16.603) (26.5.6) (72.47.6) (38.98.75) 7 bodi Express - - - - - - - 7 bodi Express - - - - - - - 7 bodi Express - - - - - - - c - - - - - - - - 7 bodi Express - - - - - - -	3		365.77	247.99	415.01	908.09	1,128.06	1,590.47	
b Charges in inventives of finished goods work in progress and stack-in-Trade 44.73 (1.05) 3.05 (1.05) -1.54 (1.05) 5.26 (1.05) (1.05) c Employee Bungh Express Finance Costs 44.73 (4.0 42.72 (1.05) 3.05 (1.05) -1.54 (1.05) 3.05 (1.05) 3.05 (1.05)	4								
c Imployee Length Expension 72.94 02.85 97.54 199.07 221.64 334.15 Filtmane Costs 44.33 4.27 132.11 120.07 337.66 34.3 Operation and Amerization Expenses 64.15 41.00 47.04 147.22 131.10 130.65 17.63 Other Expenses 24.25 239.40 351.64 1.177, 03.22.41 306.56 72.08 Formit Expenses 42.52 239.40 351.64 1.177, 12.63.22 2.09.96.4 Projet Expenses 65.75 (51.41) (166.63) (26.55) (52.476) 0.99.9.9 Current Taxes - - - - .55.9 (77.63) 0.99.9.9 Deferring Taxes - - - - .55.9 (77.63) 0.99.9.9 Total tax expenses - - - .55.9 (77.63) 0.99.9.9 Deferring Taxes - - - .55.9 (77.63) 0.9.9.9 Deferring Taxes - - .55.9 (77.63) 0.9.9.9 0.9.9.9	a							895.45	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	b							(180.71)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	c								
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	đ							24.32	
Total Expenses 423.52 299.40 587.64 1,171.70 1,682.82 1,990.4 5 Profit before arr 3-4) (59.75) (51.41) (166.03) (263.61) (524.76) (399.80) 6 Profit before arr 3-4) (59.75) (51.41) (166.03) (263.61) (524.76) (399.80) 7 Tex expresses - - - 0.1 0.1 0.1 0 Defined Taxes - - (5.54) - 0.1 0.1 7 Profit for the period (Year before non-controlling interest (5-6) (59.75) (51.41) (160.49) (263.61) (59.708) (454.44) 8 Non-controlling interest -	e					1			
5 Profit before tax 3-4) (69.75) (51.41) (166.03) (263.61) (624.76) (399.9 6 Profit period Exernses - - - - - 582 7 Text expenses - - - - 0.1 Deformed Taxes - - - 0.1 - 0.1 Deformed Taxes - - (5.54) - 0.1 Total tax expenses - - (5.54) - 0.1 Total tax expenses - - (5.54) - 0.1 Profit for the period/free before non-controlling interest (5-6) (69.75) (51.41) (160.49) (263.51) (607.08) (454.44) 10 Other comprehensitie income - <td>f</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	f								
6 Prior Period Lexenses - - 58.2 7 To te appress - - 0.1 Deferred Taxes - - 0.1 Deferred Taxes - - 0.1 Total taxe expension - (5.54) - 0.1 Profit for the period / Year before non-controlling interest (5-6) (59.75) (51.41) (160.49) (263.61) (507.08) (454.44) 8 Non-controlling interest - <		1010 Expenses	423.52	279,40	381.04	1,1/1./0	1,002.02	1,990.41	
7 Tac expenses - - - 0.1 Different Taxes - - - 0.1 Different Taxes - - 0.1 0.1 Total bac expenses - (5.54) - 0.1 Total bac expenses - (5.54) - 0.1 7 Profit for the period //ear before non-controlling interest (5-6) (59.75) (51.41) (180.49) (263.61) (507.08) (454.44) 8 Non-controlling interest -	5	Profit before tax (3-4)	(59.75)	(51.41)	(166.03)	(263.61)	(524.76)	(399.94)	
Carrent Taxes - - - 0.1 Defined Taxes - (5.54) (17.68) (3.9) Total tax exposes - (5.54) - (17.68) (3.9) Profit for the period Year before non-controlling interest (5-6) (59.75) (51.41) (160.49) (263.61) (507.08) (454.44) Non-controlling interest -	6							58.29	
Deferred Taxes - (5.54) (17.68) (3.92) Total tax expensis - - (5.54) - (17.68) (3.92) Profit for the period /tear before non-controlling interest (5-6) (59.75) (51.41) (180.49) (263.61) (507.08) (454.44) Non-controlling interest -	7			- }	- 1				
Total tax expenses - (5.54) - (17.68) (3.7 Profit for the period /Year before non-controlling interest (5-6) (59.75) (51.41) (160.49) (263.61) (507.08) (454.44) Non-controlling interest - <td< td=""><td></td><td>Current Taxes</td><td></td><td>-</td><td>-</td><td>•</td><td>-</td><td>0.18</td></td<>		Current Taxes		-	-	•	-	0.18	
7 Profit for the paried / f car before non-controlling interest (5-6) (59,75) (51,41) (160,49) (263,61) (597,08) (454,44) 8 Non-controlling interest -		Deferred Taxes		-	(5.54)		(17.68)	(3.95)	
8 Non-controlling interest - </td <td></td> <td>Total tax expenses</td> <td>-</td> <td></td> <td>(5.54)</td> <td>-</td> <td>(17.68)</td> <td>(3.77)</td>		Total tax expenses	-		(5.54)	-	(17.68)	(3.77)	
9 Profil for the period/year (7-8) (59.75) (51.41) (160.49) (263.61) (507.08) (454.44) 10 Other comprohessive income -	7	Profit for the period /Year before non-controlling interest (5-6)	(59.75)	(57.41)	(160.49)	(263.61)	(507.08)	(454.46)	
10 Other comprehensive income Items that will in the reclassified to profit or loss, net of tax Items that will be reclassified to profit or loss, net of tax Items that will be reclassified to profit or loss, net of tax Total other comprehensive income - - - 5.6 11 Non-controlling interest - - - 5.6 12 Other comprehensive income attributable to shareholders(10+11) - - - 5.6 12 Other comprehensive income attributable to: Shareholders of the Company - <td< td=""><td>8</td><td>Non-controlling interest</td><td></td><td>-</td><td>-</td><td></td><td>-</td><td>-</td></td<>	8	Non-controlling interest		-	-		-	-	
10 Other comprehensive income Items that will by the reclassified to profit or loss, net of tax Items that will by the reclassified to profit or loss, net of tax - - - - 5.6 11 Non-controlling interest - - - 5.6 12 Other comprehensive income attributable to shareholders(10+11) - - - 5.6 12 Other comprehensive income attributable to shareholders(10+11) - - - - 5.6 12 Other comprehensive income attributable to shareholders(10+11) - - - - - - 5.6 13 Non-controlling interest - <td>9</td> <td>Profit for the period/year (7-8)</td> <td>(59.75)</td> <td>(51.41)</td> <td>(160.49)</td> <td>(263.61)</td> <td>(507.08)</td> <td>(454.46)</td>	9	Profit for the period/year (7-8)	(59.75)	(51.41)	(160.49)	(263.61)	(507.08)	(454.46)	
Items that will be reclassified to profit or loss, net of tax - - - - - 5.6. Total other comprehensive income - - - - 5.6. 11 Non-controlling interest - - - 5.6. 12 Other comprehensive income attributable to shareholders(10+11) - - - - 5.6. 12 Other comprehensive income attributable to: - - - - 5.6. 12 Other comprehensive income attributable to: - - - - 5.6. 12 Other company (59.75) (51.41) (160.49) (263.61) (507.08) (448.82) Non-controlling interest -	10	Other comprehensive income		-	-		-	- 1	
Total other comprehensive income				-	-	-	-	5.63	
11 Non-controlling interest - - - - - - - 5.6. 12 Other comprehensive income attributable to shareholders(10+11) - - - - - 5.6. 12 Other comprehensive income attributable to: -	1		L	-	- [-		
12 Other comprehensive income attributable to shareholders(10+11) - - - 5.6. Total comprehensive income attributable to: Shareholders of the Company (59.75) (51.41) (160.49) (263.61) (507.08) (448.82) Non-controlling interest -								5.63	
Total comprehensive income attributable to: (59,75) (51,41) (160,49) (263,61) (507,08) (448,88) Shareholders of the Company (59,75) (51,41) (160,49) (263,61) (507,08) (448,88) Non-controlling interest (59,75) (51,41) (160,49) (263,61) (507,08) (448,88) 13 Padu up Equility Share Cognital 165,83 165,83 165,83 165,83 165,83 165,83 15 Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised) (0,72) (0,62) (1.94) (3.18) (6.12) (5.4	1								
Shareholders of the Company (59,75) (51,41) (160.49) (263.61) (507.08) (448.83) Non-controlling interest - </td <td>12</td> <td></td> <td></td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td>5.63</td>	12			-	-	-		5.63	
Non-controlling interest - </td <td></td> <td></td> <td>(70.00)</td> <td>-</td> <td>-</td> <td></td> <td>-</td> <td></td>			(70.00)	-	-		-		
Total Comprehensive income (59.75) (51.41) (160.49) (263.61) (507.08) (448.82) 13 Padi up Equity Share Capital 165.83	- 1		(59.75)	(51.41)	(160.49)	(263.61)	(507.08)	(448.83)	
13 Pad up Equily Share Capital 165.83		Non-controlling interest		-	-		-	-	
14 Other equily 15 Extrainings per Share (before Extraordinary Items) (of R-32- each) (not annualised) (a) Basic (0,72) (0.62) (1.94) (3.18) (6.12) (5.4)		Total Comprehensive income	(59.75)	(51.41)	(160.49)	(263.61)	(507.08)	(448.83)	
14 Other equity 15 Earnings per Share (before Extraordinary Items) (of R52/- each) (not annualised) (a) Basic (0,72) (0.62) (1.94) (3.18) (6.12) (5.4)	13		165.83	165.83	165.83	165.83	165.83	165.83	
(a) Basic (0.72) (0.62) (1.94) (3.18) (6.12) (5.4									
	15	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)		1		Í	1		
		(a) Basic	(0.72)	(0.62)		(3.18)	(6.12)	(5.48)	
		(b) Diluted	(0.72)	(0.60)	(1.88)	(3.09)	(5.94)	(5.32)	

NOTES:

1. The above consolidated financial results of Vivined Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 14, 2025. The statutory auditors of the Company have carried out a limited review on consolidated financial results and expressed a modified conclusion thereon.

2. These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").

3. In line with provisions of IND-AS 108 Operating segments, the Group has primarily in Pharma Segment and accordingly the segment reporting is not applicable to the company.

4. The subsidiaries (100%) considered for the consolidated financial statements for the Quarter and nine months ended December 31, 2024 are Finoso Pharma Private Limited, Virimed Labs USA Inc, Vivimed Holdings Ltd and Vivimed Labs Mauritus Ltd

5. The Company has defaulted in repayment of dues to banks and Financial Institution amounting to Rs 3,746,40 million as on 31.12.2024 as per books of account. All the total accounts is outstanding as on 31.12.2024 or the strike the banks. In view of longoing negotiation with lenders for settlement, interest for the period is not accounted.

6.Deferred tax will be calculated at the end of year.

7. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabed Date : 14.02.2025





		VIVIMED LABS	LIMITED		-		
	UNAUDITED STANDALONE FI	NANCIAL RESULTS FOR T	HE QUARTER AND N	NINE MONTHS ENDE	D 31.12.2024		
<u>S1.</u>							Rs. In Million
51. No.	Particulars		3 Months Ended		9M FY 24 31,12.2024	9M FY 23 31.12.2023	Year Ended 31.03.2024
		31.12.2024	30.09.2024	31,12,2023			
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income From Operations						
1	Revenue from Operations	342,33	221.60	371.35	810.29	1,004.11	1,367.97
	Total revenue from operations	342.33	221.60	371.35	810.29	1,004.11	1,367.97
2		0.03	0.27	0.37	0.33	22.03	95.72
3	Total Revenue (1+2)	342.36	221.87	371.73	810.62	1,026.15	1,463.70
4	Expenses					······································	
a	Cost of material consumed	158.11	150.22	197.64	477.87	544.69	853.87
b	Changes in inventories of finished goods work in progress and stock-in-Trade	56.06	(41.05)	3.05	(9.61)	5.26	(180.70)
с	Employee Benefit Expenses	59.26	50.91	85.93	159.69	237.57	294.48
d	Finance Costs	4.31	3.73	131.57	10.55	355.95	19.04
е	Depreciation and Amortisation Expenses	63.67	38.62	44.85	140.19	134.55	184.10
f	Other Expenses	70.69	69.37	75.90	302.72	264.75	678.43
	Total Expenses	412.10	271.80	538.94	1,081.41	1,542.77	1,849.22
5	Profit before tax (3-4)	(69. 74)	(49.93)	(167.22)	(270.79)	(516.63)	(385.52)
6	Tax Expenses	-	-			-	58.29
	Current Taxes	-	-	-	-	-	-
	Deferred Taxes		-	(5.54)		(17.68)	-
	Total tax expenses	-	-	(5.54)	-	(17.68)	-
7	Profit for the period /Year (5-6)	(69. 74)	(49.93)	(161.68)	(270.79)	(498.95)	(443.81)
8	Other Comprehensive income	-	-	-	-	-	-
	Items that will not be reclassified to profit or loss, net of tax	-	-	-	-	-	4.76
	Items that will be reclassified to profit or loss, net of tux		-	-	-	-	-
	Total other comprehensive income	-	-		-	· _	4.76
9	Total comprehensive income (7+8)	(69.74)	(49.93)	(161.68)	(270.79)	(498.95)	(439.05)
	Paid up Equity Share Capital	165.83	165.83	165.83	165.83	165.83	165.83
	Other equity						
	Earnings per Share (before Extraordinary Items) (of Rs2/- each)	1					
	(a) Basic	(0.84)	(0.60)	(1.95)	(3.27)	(6.02)	(5.35)
	(b) Diluted	(0.82)	(0.58)	(1.89)	(3.17)	(5.84)	(5.20)

NOTES:

1. The above standalone financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 14, 2025. The statutory auditors of the Company have carried out a limited review on standalone financial results and expressed a modified conclusion thereon.

2. These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").

3. In line with provisions of IND-AS 108 Operating segments, the Company has primarily in Pharma Segment and accordingly the segment reporting is not applicable to the company.

4. The Company has defaulted in repayment of dues to banks and Financial Institution amounting to Rs 3,746.40 million as on 31.12.2024 as per books of account. All the loan accounts outstanding as on 31.12.2024 are classified as NPA by the banks. In view of ongoing negotiation with lenders for settlement, interest for the period is not accounted.

5. Deferred tax will be calculated at the end of year.

6. Corresponding numbers of previous period / year have been regrouped, wherever necessary.



For VIVIMED LABS LYMITED (SANTOSH (ARALWAR)

(SANTOSHYARALWAR) MANAGING DIRECTOR

Place: Hyderabad Date: 14.02.2025



A. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Not Applicable for the Quarter ended December 31, 2024.

B. DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES.

The Company has defaulted in repayment of dues to banks and Financial Institution amounting to Rs 3,746.40 million as on 31.12.2024 as per books of account. All the loan accounts outstanding as on 31.12.2024 are classified as NPA by the banks. In view of ongoing negotiation with lenders for settlement, interest for the period is not accounted.

C. DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for halfyearly filings i.e., 2nd and 4th quarter)

Not Applicable for Quarter ended December 31, 2024.

D. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)

Not Applicable for Quarter ended December 31, 2024.

Yours faithfully For VIVIMED LABS LIMITED

SANTOSH VARALWAR MANAGING DIRECTOR



Vivimed Labs Limited. CIN:L02411KA1988PLC009465 Registered Office: #78/A, Kolhar Industrial Area. Bidar, Kamataka - 585 403, India. T +91(0) 8462-232045. F +91(0) 8482-232436 Email: info@vivimedlabs.com | <u>www.vivimedlabs.com</u>

Corporate Office:

6-3-866/1/G1, 3rd Floor, GMR Towers, Greenlands, Begumpet, Hyderabad, Telangana – 500 016, India. GSTIN: 36AAACV6D60A 12Q T +91(0) 40-6608-6608. F +91(0) 40-6608-6699





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Vivimed Labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Vivimed Labs Limited

- 1. We have reviewed the accompanying "Statement of Unaudited Consolidated Financial Results (the "Statement") of Vivimed Labs Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its associates attached herewith for the quarter ended and nine months ended December 31, 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified u/s 143(10) of The Companies act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by SEBI under egulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Holding Company Vivimed Labs Limited

Subsidiaries

Finoso Pharma Private Limited
Vivimed Holdings Limited
Vivimed Labs USA INC.
Vivimed Labs Mauritius Limited



5. Basis for Qualified Conclusion

Based on information provided to us by management, Holding Company has not provided for interest expenses of ₹ 88.18 million on an accrual basis for the Quarter ended 31.12.2024 (₹256.22 million for the year to date 31.12.2024), pertaining to loans [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards.

6. Qualified Conclusion

Based on our review, with the exception of the matter described in the preceding paragraph,, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. Other Matters:

The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of subsidiaries, whose interim financial results and other financial information reflect total revenues of ≤ 53.42 million for the quarter ended 31-12-2024 (≤ 127.48 million for the year to date 31.12.2024), and total net profit ≤ 9.46 million for the quarter ended 31-12-2024 (≤ 6.63 million for the year to date 31.12.2024), as considered in the "Statement" whose interim financial results and other financial information have not been reviewed by their auditors;

These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on "the Statement", in so far as it relates to the affairs of subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information.

Our conclusion on "the Statement" in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management.

Also, we have not audited or reviewed the comparative financial information appearing in the statement of the corresponding quarter ended 31st December 2023. The comparative financial information appearing in the statement of the corresponding quarter ended 31st December 2023 are audited by the previous auditor whose report dated 14.02.2024, expressed a modified opinion on those Consolidated financial results.

Our Conclusion is not modified in respect of this matter.

For SVRL & Co. **Chartered Accountants** Firm's Regn No: 0160828 ww FRN: 016182S HYDERABAD G Rămakrishr ACC Partner M. No. 213487

Place: Hyderabad Date: 14-02-2025 UDIN: 25213487BMMMJ08419





Independent Auditor's Review Report on the Quarterly Unaudited Standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Review report to THE BOARD OF DIRECTORS M/S VIVIMED LABS LIMITED

- We have reviewed the accompanying statement of Unaudited Standalone Financial Results of VIVIMED LABS LIMITED ("the Company"), for the Quarter and nine months ended December 31, 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 as amended from time to time ("the Listing Regulations").
- 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified u/s 143(10) of The Companies act, 2013 and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Basis for Qualified Conclusion

Based on information provided to us by management, Vivimed Labs Limited has not provided for interest expenses of ₹ 88.18 million on an accrual basis for the Quarter ended 31.12.2024 (₹ 256.22 million for year to date 31.12.2024), pertaining to loans [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards

5. Qualified Conclusion

Based on our review, with the exception of the matter described in the preceding paragraph, nothing has come to our attention that causes us to believe that the accompanying

statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid 'Ind AS 34" Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters:

We have not audited or reviewed the comparative financial information appearing in the statement of the corresponding quarter ended 31st December 2023. The comparative financial information appearing in the statement of the corresponding quarter ended 31st December 2023 are audited by the previous auditor whose report dated 14.02.2024, expressed a modified opinion on those Standalone financial statements.

Our Conclusion is not modified in respect of this matter.

For SVRL & Co. Chartered Accountants Firm's Regn No: 01618258

> FRN : 016182S HYDERABAD.

> > ACC

and

Place: Hyderabad Date: 14-02-2025 UDIN: 25213487BMMMJN8524 G Ramakrishna Partner M. No. 213487